时隔一年,康方生物再次经历戏剧性一周。4月底,公司宣布核心双抗产品依沃西在“头对头”临床试验中击败国内创新药领军企业百济神州的产品,并在美国获批两个适应症,成为首个由中国公司独立主导的创新生物药。同时,依沃西在国内第二个适应症获批上市。利好消息推动康方股价创下历史新高,创始人夏瑜表示,经过5年波折,股价从发行价16.1港元涨至超100港元。但随后持有依沃西海外权益的Summit公司股价暴跌36%,...
Source Link时隔一年,康方生物再次经历戏剧性一周。4月底,公司宣布核心双抗产品依沃西在“头对头”临床试验中击败国内创新药领军企业百济神州的产品,并在美国获批两个适应症,成为首个由中国公司独立主导的创新生物药。同时,依沃西在国内第二个适应症获批上市。利好消息推动康方股价创下历史新高,创始人夏瑜表示,经过5年波折,股价从发行价16.1港元涨至超100港元。但随后持有依沃西海外权益的Summit公司股价暴跌36%,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.